Medical Laboratory Technology and Diagnostics: Market, Workforce and Access Report

Summary

Medical laboratory technology and diagnostics sits between clinical decisions and patient care, and its market is large but poorly measured. Market research vendors value global clinical laboratory services at about USD 224.4 billion and forecast a 4.3% compound annual growth rate ¹. Estimates for related categories differ widely ²³⁴⁵, so no reconciled global figure is available. Laboratories are reported to perform more than 13 billion tests a year, but that count comes from a vendor without a primary source ⁶. The most important evidence concerns workforce, with a projected 24,000 clinical laboratory technologist vacancies a year in the United States ⁷, and access, with unequal and intermittent testing in Kenyan hospitals ¹¹ and wide disparities across the Western Pacific Region ¹². Principal risks are staffing shortages, unverified market data and unequal access. The outlook points to continued growth in testing capacity, but staffing and access constraints are likely to limit how fast that growth reaches patients. Decision makers should verify vendor figures before relying on them.

Key findings

1. 1

   Market estimates are high in value but do not agree

   Vendor estimates for the global market range from about USD 86.5 billion for clinical diagnostics to US$ 407.68 billion for diagnostic labs. The gap reflects different market boundaries as much as growth, so no single global figure should be used without checking definitions ¹²³⁴⁵.

   Confidence: Medium
2. 2

   Workforce shortage is the clearest verified constraint

   The US Bureau of Labor Statistics projection cited by an industry association shows more than 24,000 clinical lab technologist vacancies a year over the next decade, while only 7,400 medical lab technicians and scientists earned degrees in the latest single year reported ⁷. Peer-reviewed reviews describe critical shortages in laboratories ⁸⁹.

   Confidence: Medium
3. 3

   Access to laboratory testing is unequal

   A study of Kenyan general hospitals found access to laboratory testing to be unequal and intermittent, and several large private facilities and tertiary hospitals did not submit monthly testing reports ¹¹. A Western Pacific qualitative evaluation found significant disparities between and within countries, with patients traveling long distances or waiting extended periods ¹².

   Confidence: Medium
4. 4

   Testing volume and automation are large but partly unverified

   Business Research Insights reports more than 13 billion laboratory tests a year and more than 320,000 automated analyzers worldwide ⁶. The test count comes from a market research vendor without a primary source, so the analyzer count is the more reliable indicator of installed capacity, and even it is a vendor figure.

   Confidence: Qualitative
5. 5

   Access evidence is largely qualitative or regional

   The Lancet Commission figure cited by WHO African Region proceedings states that 47% of the world population has little or no access to diagnostics, and WHO African Region notes that laboratory services receive little or no attention in many countries ¹³. No comparable national access percentages were verified for Kenya or the Western Pacific Region.

   Confidence: Medium
6. 6

   Proposed US workforce legislation has not been verified as enacted

   The Medical Laboratory Personnel Shortage Relief Act would add lab personnel to the National Health Service Corps and create federal training grants. The source reports reintroduction, so it should be treated as a proposal and not as binding law ¹⁰.

   Confidence: High

1Industry definition and scope

This report covers medical laboratory technology and diagnostics: the staffed laboratories, testing services, automated analyzers and reagents that produce clinical test results used in diagnosis, treatment and monitoring. The geographic scope is global, with US workforce and reimbursement examples and regional access evidence from the African Region and the Western Pacific Region, plus Kenya. The brief also names Ethiopia, but the source pack contains no Ethiopia-specific evidence, so none is reported. The reporting period is the latest available data. Market estimates come from vendor publications, while workforce and access evidence comes from several publications over different periods ^169111213.

Market publishers use different labels for overlapping markets. Clinical laboratory services, clinical laboratory tests, clinical diagnostics and diagnostic labs are reported as separate categories ¹²³⁴⁵. The pack does not define their boundaries, so these labels should not be treated as interchangeable.

The segments covered are test volumes and automation, the medical laboratory workforce, access to essential laboratory services and public health reporting. The workforce focus uses US terms for medical laboratory scientists and technicians ⁹. Established practice here means routine testing on automated analyzers ⁶. Evidence on emerging or experimental approaches in the pack is limited, so this report does not assess them in depth.

Scope follows the source pack. Definitions were not standardized across sources.

2Market size, structure and value chain

Vendor estimates place the global clinical laboratory services market at about USD 224.4 billion, with a forecast growth to USD 308.2 billion and a projected compound annual growth rate of 4.3% ¹. The clinical laboratory tests market is estimated at USD 139.2 billion, with growth forecast to USD 282.2 billion ². Clinical diagnostics is estimated at USD 88.79 billion ³ and at USD 86.5 billion with a forecast CAGR of 5.5% ⁴. Diagnostic labs are valued at US$ 407.68 billion with an 8.24% CAGR forecast ⁵. The table sets out these figures side by side. Each value is a vendor estimate or forecast, not an observed market total.

The spread between these figures is wide, and the pack offers no reconciled global series. The most likely explanation is differing scope, so the spread should be read as a limit on precision rather than as evidence of a particular market size.

Market structure is described in the pack only by named leaders. Quest Diagnostics, Eurofins Scientific and Laboratory Corporation of America Holdings are listed among market leaders ⁵. The pack gives no revenue shares, concentration ratios or regional breakdowns, so the degree of concentration cannot be measured.

The value chain runs from analyzer and reagent suppliers to laboratories, which may be hospital, independent or public, to clinicians who order tests and to payers. The installed base of more than 320,000 automated analyzers indicates the scale of supplier placements ⁶. Revenue models such as test fees, instrument sales and reagent contracts are not quantified in the pack. For context, an older national status report estimated that laboratory services account for 2.3% of US total health care expenditure, while being essential for safe care ¹⁵. No current US figure was verified.

• Laboratory tests performed globally each year 13billion tests per year Observed Global, Latest available data [6]
• Automated laboratory analyzers operating worldwide 320,000analyzers Observed Global, Latest available data [6]

Figures are copied from the source pack. No reconciled series was constructed.

3Customers, demand and adoption

Demand comes from patients, clinicians, public health programs and payers. The pack links rising testing demand to the burden of disease. WHO estimates, as cited in one source, put noncommunicable diseases at nearly 43 million deaths a year, about 74% of global deaths ². A review states that laboratories face a critical shortage of scientists and technicians amid rising testing demand ⁹. These sources support the direction of demand but do not quantify test growth by disease or setting.

Purchasing criteria are not covered by verified survey data in the pack. WHO promotes an essential in vitro diagnostic list and a priority medical devices list to support national access and availability ¹⁴. Those lists point to access, availability and reliability as public priorities, but they are guidance, not evidence of buyer behavior.

Barriers to access are the strongest evidence in the pack. The Lancet Commission figure cited by WHO African Region proceedings states that 47% of the world population has little or no access to diagnostics ¹³. That source is undated in its own citation, so it should be read as a broad indicator. Kenyan hospitals show unequal and intermittent testing ¹¹, and Western Pacific patients may travel long distances or wait extended periods ¹².

Adoption signals are mixed. Vendor research cites China as the fastest-growing single country, at a 7.2% CAGR forecast, driven by hospital laboratory modernization ⁴. Another vendor identifies Asia-Pacific as the fastest-growing regional market, without a figure ³. These are forecasts from market research, not observed adoption rates. Verified waiting-time and turnaround-time data for public and private settings are not available in the pack.

Demand indicators are drawn from disease burden and access evidence. No demand survey was verified.

4Competitive landscape and key players

The pack supports a limited comparison of provider types. Public hospitals, private laboratories and community or primary care facilities all appear in access evidence, but it is not broken down by provider type. In Kenya, several large private facilities and tertiary hospitals failed to submit monthly laboratory testing reports to the national system over a 24-month study period ¹¹. This shows a reporting gap that makes private and tertiary activity hard to see. It is not evidence that private or public quality differs.

In the Western Pacific Region, the evaluation found significant disparities in access to essential laboratory services at the primary care level, both between and within countries ¹². The pack does not show whether these disparities differ by ownership, so no public versus private conclusion is drawn.

Named companies are limited to the market leaders Quest Diagnostics, Eurofins Scientific and Laboratory Corporation of America Holdings ⁵. The pack gives no revenue, test volumes, pricing, footprint or business model detail for them. A fair comparison of their models, quality records or differentiation is therefore not possible from this evidence. Comparable company examples were limited.

Competitive pressure can be inferred only in general terms. Large installed bases of automated analyzers ⁶ suggest that scale and instrument placement matter, but the pack does not attribute analyzer share to any supplier. Concentration cannot be measured, and the report does not claim a specific competitive structure.

Company comparison is limited to names. Provider-type evidence is regional or qualitative.

5Technology, operations and workforce

Automation is established practice. More than 320,000 automated laboratory analyzers were reported as operating worldwide ⁶. An older national status report also notes that more than 4,000 laboratory tests are available for clinical use in the United States ¹⁵. Digital health and laboratory informatics adoption rates are not verified by provider type. Kenyan evidence shows that reporting depends on data systems such as DHIS2, and that gaps in submission weaken visibility ¹¹. Emerging or experimental technologies are not evidenced in the pack, so no assessment of them is made here.

Workforce shortage is the central operational constraint. In the United States, 335,500 medical laboratory scientist and technologist jobs were counted in the latest available period ⁹. A review cites a projected 11% annual growth in jobs to fill ⁹. The Bureau of Labor Statistics projects more than 24,000 clinical lab technologist vacancies a year over the next decade, while only 7,400 medical lab technicians and scientists earned degrees in the latest single year reported ⁷. These two figures measure different things, so the gap is indicative rather than a precise shortfall.

Professional bodies report the same pressure. ASCLS has stated that the profession is educating less than half of the number of laboratory professionals needed, and ASCP vacancy survey findings show retirement rates accelerating across most laboratory departments ¹⁶. Peer-reviewed work notes a shortage of qualified personnel in clinical microbiology laboratories ⁸. The pack contains no verified global headcount or vacancy rate outside the United States.

• Projected clinical lab technologist vacancies 24,000vacancies per year Forecast United States, Projected over the next decade [7]
• Medical lab technicians and scientists awarded degrees 7,400degrees awarded Observed United States, Latest available data [7]

The workforce comparison combines a projection with a single-year count, so it is not a like-for-like calculation.

6Regulation, standards, risk and sustainability

The jurisdictions in the pack are the United States and WHO global guidance. Binding requirements must be separated from proposals and voluntary guidance. The WHO essential in vitro diagnostic list and priority medical devices list are supportive guidance to national access and availability ¹⁴. They do not themselves impose national legal obligations. WHO also supports national laboratory systems to deliver timely, safe and reliable diagnostic results ¹⁴, which states an expectation rather than a measured standard.

The Medical Laboratory Personnel Shortage Relief Act was reintroduced in the United States as a proposal. It would add lab personnel to the National Health Service Corps and create federal training grants ¹⁰. The source does not show that it has been enacted, so it should be treated as a proposed rule. The pack does not identify any enacted US laboratory licensing, accreditation or quality rule, and this gap should be checked against primary legal sources before any compliance conclusion is drawn.

Evidence standards for test quality are not verified in the pack. No recent data link laboratory test quality or timeliness to patient outcomes . Privacy, data protection and environmental or social factors are not covered by verified sources in the pack. Operational risks include staffing shortages ⁸⁹¹⁶ and long travel or waiting times in primary care ¹². This section is general industry analysis and is not medical, legal or engineering advice.

No binding US laboratory standards were verified in the pack. Proposed legislation is reported as proposed.

7Challenges, opportunities and case examples

The main constraints are workforce supply, unequal access, weak data and limited affordability evidence. Staffing shortages are documented across US sources ⁷⁹¹⁶. Access is uneven in Kenya ¹¹ and across the Western Pacific Region ¹². Affordability cannot be assessed with current data: the only cost share in the pack is an older US estimate of 2.3% of total health care expenditure ¹⁵, and no verified reimbursement rates were found for the current period.

Opportunities include growing demand forecasts ¹⁴, hospital laboratory modernization in China ⁴, and the expanded access focus of WHO priority lists ¹⁴. A proposed US bill could expand the workforce pipeline if enacted ¹⁰. These are interpretations of the evidence, not verified outcomes.

Case example one is Kenya. A study of general hospital reporting found that access to laboratory testing is unequal and intermittent, and that several large private facilities and tertiary hospitals did not report to DHIS2 ¹¹. The lesson is that access cannot be measured where reporting is incomplete. Case example two is the Western Pacific Region, where primary care patients may travel long distances or wait extended periods, delaying diagnosis and treatment ¹². Case example three is the market leaders named in the pack: Quest Diagnostics, Eurofins Scientific and Laboratory Corporation of America Holdings ⁵. The pack gives no operational data for them, so they illustrate scale only.

Examples are limited to sources in the pack. Two regional case examples and one company example are used.

8Outlook and strategic implications

In the near term, vendor forecasts point to continued growth, with CAGRs from 4.3% ¹ to 8.24% ⁵. These ranges are wide and rest on undisclosed assumptions, so they should be treated as directional. In the medium term, the main limit on growth is likely to be staffing and access rather than demand. The workforce projections ⁷ and the ASCLS statement ¹⁶ suggest that testing capacity may not keep pace with volume unless the pipeline widens.

Key uncertainties include the lack of a reconciled market size, the absence of verified waiting-time and digital health data, and unclear outcome links to test quality. The status of the US shortage bill ¹⁰ will determine whether a policy response becomes binding.

Practical implications differ by stakeholder. Laboratories should plan for staffing constraints and test reporting quality. Suppliers should test vendor growth claims against regional demand before committing to modernization markets ⁴. Public health planners should use WHO priority lists ¹⁴ alongside local reporting data, which may be incomplete ¹¹. Investors and analysts should verify market figures before use. This is not investment advice.

Outlook reflects the balance of vendor forecasts and qualitative access and workforce evidence.

9Conclusion

Medical laboratory technology and diagnostics is a large, growing service whose capacity depends on people and access as much as on equipment. The most defensible takeaways are that workforce supply is a verified constraint, that access is uneven where evidence exists, and that vendor market values differ too widely to be used without checking definitions.

How this was built

Sources

1. 1

   Clinical Laboratory Services Market Size Report

   Grand View Research Market research

   grandviewresearch.com
2. 2

   Clinical Laboratory Tests Market Size Report

   Grand View Research Market research

   grandviewresearch.com
3. 3

   Clinical Diagnostics Market Size, Forecast, Industry Growth & Share

   Mordor Intelligence Market research

   mordorintelligence.com
4. 4

   Clinical Diagnostics Market Forecast Outlook

   Future Market Insights Market research

   futuremarketinsights.com
5. 5

   Diagnostic Labs Market Size, Trends & Forecast

   The Insight Partners Market research

   theinsightpartners.com
6. 6

   Laboratory Diagnostics Market Size & Industry Report

   Business Research Insights Market research

   businessresearchinsights.com
7. 7

   Building Tomorrow's Lab Workforce

   American Medical Technologists Industry association

   americanmedtech.org
8. 8

   The Hidden Crisis in the Times of COVID-19: Critical Shortages of Medical Laboratory Professionals in Clinical Microbiology

   Peer-reviewed review (PubMed Central) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
9. 9

   A Literature Review on How We Can Address Medical Laboratory Scientist Staffing Shortages

   Halstead DC, Sautter RL; Laboratory Medicine Peer-reviewed

   doi.org
10. 10

    Medical Laboratory Personnel Shortage Relief Act Reintroduced to Combat Workforce Crisis

    Dark Daily News report

    darkdaily.com
11. 11

    Reporting of diagnostic and laboratory tests by general hospitals as an indication of access to diagnostic laboratory services in Kenya

    Bahati F et al.; PLOS ONE Peer-reviewed

    journals.plos.org
12. 12

    A qualitative evaluation of access to essential laboratory services for communicable diseases at the primary health care level in the Western Pacific Region

    Tropical Medicine and Health (BioMed Central) Peer-reviewed

    ncbi.nlm.nih.gov
13. 13

    WHO African Region national heads of units of diagnostics and laboratory services meetings proceedings

    World Health Organization African Region; Global Health Action / PubMed Central Peer-reviewed

    ncbi.nlm.nih.gov
14. 14

    Diagnostics - Global

    World Health Organization Regulator

    who.int
15. 15

    Laboratory Medicine: A National Status Report

    The Lewin Group for CDC (Laboratory Medicine national status report) Official statistics

    cdc.gov
16. 16

    The clinical laboratory workforce shortage (The quiet crisis)

    ADLM (Association for Diagnostics and Laboratory Medicine), Clinical Lab News Industry association

    myadlm.org